A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 518-524

  Kim, Kenneth H ^a   Dmitriev, Igor P ^b   Saddekni, Souheil ^c   Kashentseva, Elena A ^b   Harris, Raymond D ^d   Aurigemma, Rosemarie ^e   Bae, Sejong ^c   Singh, Karan P ^c   Siegal, Gene P ^f   Curiel, David T ^b   Alvarez, Ronald D ^g  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CRAd; Gene therapy; Infectivity enhanced adenoviral vectors; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CONDITIONALLY REPLICATING ADENOVIRUS;

ADULT; AGED; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER GRADING; CHILL; CLINICAL ARTICLE; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; GENE TRANSFER; HUMAN; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS SHEDDING;

CRAD; GENE THERAPY; INFECTIVITY-ENHANCED ADENOVIRAL VECTORS; OVARIAN CANCER;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ASCITES; CA-125 ANTIGEN; CHILLS; DISEASE PROGRESSION; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84882452568     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.003     Document Type: Article

References (31)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
3. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 21 2003 3194 3200
4. R.E. Bristow, and J.S. Berek Surgery for ovarian cancer: how to improve survival Lancet 367 2006 1558 1560
5. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
6. K.J. Kimball, T.M. Numnum, R.P. Rocconi, and R.D. Alvarez Gene therapy for ovarian cancer Curr Oncol Rep 8 2006 441 447
7. A. Kanerva, M. Raki, and A. Hemminki Gene therapy of gynaecological diseases Expert Opin Biol Ther 7 2007 1347 1361
8. J. Nemunaitis, C. Cunningham, A. Buchanan, A. Blackburn, G. Edelman, and P. Maples Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility, and biological activity Gene Ther 8 2001 746 759
9. P.A. Vasey, L.N. Schulman, S. Campos, J. Davis, M. Gore, and S. Johnston Phase I trial of intraperitoneal injection of the E1B-55kd-gene deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 20 2002 1562 1569
10. J.T. Douglas, M. Kim, L.A. Sumerel, D.E. Carey, and D.T. Curiel Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary Ad receptors Cancer Res 61 2001 813 817
11. M. Kim, K.R. Zinn, B.G. Barnett, L.A. Sumerel, V. Krasnykh, and D.T. Curiel The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells Eur J Cancer 38 14 2002 1917 1926
12. A. Kanerva, G.V. Mikheeva, V. Krasnykh, C.J. Coolidge, J.T. Lam, and P.J. Mahasreshti Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells Clin Cancer Res 8 1 2002 275 280
13. A. Kanerva, M. Wang, G.J. Bauerschmitz, J.T. Lam, R.A. Desmond, and S.M. Bhoola Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses Mol Ther 5 6 2002 695 704
14. A. Kanerva, K.R. Zinn, T.R. Chaudhuri, J.T. Lam, K. Suzuki, and T.G. Uil Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus Mol Ther 8 3 2003 449 458
15. C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, and A. Williams An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 6 10 2000 1134 1139
16. J. Fueyo, C. Gomez-Manzano, R. Alemany, P.S. Lee, T.J. McDonnell, and P. Mitlianga A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 19 1 2000 2 12
17. K.H. Kim, M.J. Ryan, J.E. Estep, B.M. Miniard, T.L. Rudge, and J.O. Peggins A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of Ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients Hum Gene Ther 22 7 2011 821 828
18. R.D. Alvarez, M.N. Barnes, J. Gomez-Navarro, M. Wang, T.V. Strong, and W. Arafat A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial Clin Cancer Res 6 8 2000 3081 3087
19. T.G. Uil, T. Seki, I. Dmitriev, E. Kashentseva, J.T. Douglas, and M.G. Rots Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob Cancer Gene Ther 10 2 2003 121 124
20. K. Suzuki, R. Alemany, M. Yamamoto, and D.T. Curiel The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses Clin Cancer Res 8 11 2002 3348 3359
21. G.J. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, and T. Thigpen Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21 2011 419 423
22. R.D. Alvarez, and D.T. Curiel A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients Hum Gene Ther 8 5 1997 597 613
23. K.J. Kimball, M.A. Preuss, M.N. Barnes, M. Wang, G.P. Siegal, and W. Wan A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases Clin Cancer Res 16 21 2010 5277 5287
24. K.H. Kim, I. Dmitriev, J.P. O'Malley, M. Wang, S. Saddekni, and Z. You A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer Clin Cancer Res 18 12 2012 3440 3451
25. A. Koski, L. Kangasniemi, S. Escutenaire, S. Pesonen, V. Cerullo, and I. Diaconu Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF Mol Ther 18 10 2010 1874 1884
26. G. Bauerschmitz, J. Lam, A. Kanerva, K. Suzuki, D.M. Nettelbeck, and I. Dmitriev Treatment of ovarian cancer with a tropism modified oncolytic adenovirus Cancer Res 62 2002 1266 1269
27. J.G. Page, B. Tian, K. Schweikart, J. Tomaszewski, R. Harris, and T. Broadt Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer Am J Obstet Gynecol 196 2007 389e1 389e10
28. R.M. Bernal, S. Sharma, B.K. Gardner, J.T. Douglas, J.M. Bergelson, and S.M. Dubinett Soluble coxsackie adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu Clin Cancer Res 8 6 2002 Jun 1915 1923
29. T. Hara, S. Kuriyama, H. Kiyohara, Y. Nagase, M. Matsumoto, and T. Seya Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects Clin Exp Immunol 89 3 1992 Sep 490 494
30. H. Wang, I. Beyer, J. Persson, H. Song, Z. Li, and M. Richter A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses J Virol 86 11 2012 Jun 6286 6302
31. M. Raki, M. Sarkioja, R.A. Desmond, D.T. Chen, R. Butzow, and A. Hemminki Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer Gynecol Oncol 108 1 2008 166 172